Supplementary Table 1.
Characteristics of IBD Patients Who Received mRNA-Vector Vaccines
| Variable | mRNA-1273 n = 65 (36.9%) |
BNT162b2 n = 111 (63.1%) |
Overall n = 176 | P value |
|---|---|---|---|---|
| Age at dose #1, y | 47.5 ± 17.4 (43; 33–63) | 47.1 ± 15.3 (47; 33–59) | 47.3 ± 16.0 (47; 33–60.5) | .890 |
| Female | 42 (64.6) | 77 (69.4) | 119 (67.6) | .515 |
| Prior history of COVID-19 | 6 (9.2) | 10 (9) | 16 (9.1) | .961 |
| Crohn's disease | 43 (66.2) | 69 (62.7) | 112 (64) | .648 |
| Ulcerative colitis extent | ||||
| E1 | 1 (4.6) | (0) | 1 (1.6) | .345 |
| E2 | 9 (40.9) | 20 (50) | 29 (46.8) | |
| E3 | 12 (54.6) | 20 (50) | 32 (51.6) | |
| Ulcerative colitis severity | ||||
| S0 | 3 (13.6) | 7 (17.5) | 10 (16.1) | .971 |
| S1 | 8 (36.4) | 15 (37.5) | 23 (37.1) | |
| S2 | 4 (18.2) | 6 (15) | 10 (16.1) | |
| S3 | 7 (31.8) | 12 (30) | 19 (30.7) | |
| Crohn’s disease classification | ||||
| A1 | 5 (11.6) | 10 (14.7) | 15 (13.5) | .026 |
| A2 | 23 (53.5) | 49 (72.1) | 72 (64.9) | |
| A3 | 15 (34.9) | 9 (13.2) | 24 (21.6) | |
| L1 | 10 (23.3) | 27 (39.7) | 37 (33.3) | .073 |
| L2 | 8 (18.6) | 11 (16.2) | 19 (17.1) | .741 |
| L3 | 25 (58.1) | 30 (44.1) | 55 (49.6) | .150 |
| L4 | 2 (4.7) | 1 (1.5) | 3 (2.7) | .314 |
| B1 | 17 (100) | 30 (96.8) | 47 (97.9) | .454 |
| B2 | 18 (100) | 20 (95.2) | 38 (97.4) | .348 |
| B3 | 11 (100) | 20 (95.2) | 31 (96.9) | .462 |
| Perianal disease | 7 (100) | 12 (92.3) | 19 (95) | .452 |
| Biologics/SM within 3 mo of dose #1 | ||||
| No biologic/SM | 20 (30.8) | 35 (31.5) | 55 (31.3) | .474 |
| IFX/ADA/CTZ | 14 (21.5) | 33 (29.7) | 47 (26.7) | |
| UST | 22 (33.9) | 25 (22.5) | 47 (26.7) | |
| VDZ | 6 (9.2) | 14 (12.6) | 20 (11.4) | |
| Tofacitinib | 3 (4.6) | 4 (3.6) | 7 (4) | |
| Prednisone ≥20 mg/day within 30 days of 1st dose | 4 (6.2) | 3 (2.7) | 7 (4) | .258 |
| Immunomodulators | 11 (16.9) | 7 (6.3) | 18 (10.2) | .025 |
| Anti-TNF-α + IMM | 2 (14.3) | 2 (6.1) | 4 (8.5) | .355 |
| Vaccination-related data | ||||
| Above median anti-S total Ab (≥477 μ/mL) | 46 (70.8) | 66 (59.5) | 112 (63.6) | .132 |
| Vaccine nonresponder | 1 (1.5) | 3 (2.7) | 4 (2.3) | .617 |
| Titer testing interval (days since dose #2) | 131 ± 60 (145; 81–174) | 124 ± 51 (123; 91–161) | 126 ± 54 (126; 89–162) | .441 |
| Anti-S total Ab titer (μ/mL) (n = 128) | 759.8 ± 713.0 (GM: 340) (593; 107–1256) | 610.6 ± 601.8 (GM: 291) (445; 140–982) | 659.6 ± 641.5 (GM: 305) (477; 125–1107) | .225 |
| ln(anti-S total Ab) titer (μ/mL) (n = 128) | 5.83 ± 1.61 (6.38; 4.67–7.14) | 5.67 ± 1.51 (6.10; 4.94–6.88) | 5.72 ± 1.54 (6.17; 4.82–7.01) | .661 |
| Disease activity markers | ||||
| Any albumin <3.5 mg/dL (from 60 d before dose #1 up to titer date) | 15 (25.4) | 15 (16.3) | 30 (19.9) | .171 |
| Mean albumin (g/dL; from 60 d before dose #1 up to titer date) (n = 151) | 3.91 ± 0.45 (3.9; 3.7–4.2) | 4.06 ± 0.47 (4.2; 3.85–4.4) | 4.00 ± 0.47 (4.1; 3.8–4.3) | .042 |
| Any FCP ≥250 μg/g (from 60 d before dose #1 up to titer date) | 16 (57.1) | 17 (50) | 33 (53.2) | .575 |
| Mean FCP (μg/g; from 60 d before dose #1 up to titer date) (n = 62) | 397.2 ± 471.2 (291; 77–492) | 447.1 ± 671.6 (205; 43–437) | 424.6 ± 585.6 (239; 66.5–486) | .741 |
| Any CRP ≥1 mg/dL (from 30 d before dose #1 up to titer date) | 18 (40) | 12 (16.4) | 30 (25.4) | .004 |
| Mean CRP (mg/dL; from 30 d before dose #1 up to titer date) (n = 59) | 1.02 ± 1.84 (0.4; <0.04–1.3) | 0.68 ± 1.72 (<0.04; <0.04–0.4) | 0.81 ± 1.77 (<0.04; <0.04–0.80) | .309 |
NOTE. Values are n (%) or mean ± SD (median; IQR).
ADA, adalimumab; anti-S, anti-spike; CRP, C-reactive protein; CTZ, certolizumab; FCP, fecal calprotectin; GM, geometric mean; IBD, inflammatory bowel disease; IFX, infliximab; IMM, immunomodulators; IQR, interquartile range; ln, natural logarithm; SD, standard deviation; SM, small molecule; TNF, tumor necrosis factor; UST, ustekinumab; VDZ, vedolizumab.